Guanhao Biotech Co.,Ltd. (SHE:300238)

China · Delayed Price · Currency is CNY

11.25

-0.14 (-1.23%)

Oct 14, 2026, 1:35 PM CST

Market Cap	3.09B -23.3%
Revenue (ttm)	361.40M -7.0%
Net Income	17.18M -37.9%
EPS	0.06 -37.8%
Shares Out	274.70M
PE Ratio	182.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,892,600
Open	11.60
Previous Close	11.39
Day's Range	11.15 - 11.60
52-Week Range	10.19 - 18.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 535

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300238

Full Company Profile

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.

Financial Statements